XmAb7195

Phase 1Small molecule

XXencor, Inc.

XmAb7195 is one of 29 small molecule programs targeting Allergic Conjunctivitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic ConjunctivitisActive, not recruiting

Allergic ConjunctivitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

95 competitors in Allergic Conjunctivitis

#DrugCompanyPhaseTrials

Alphagan

AbbVie

Phase 3

—2

Decadron

AAspen Global Incorporated

Phase 3

4 3

Bromday

BBausch Health Americas, Inc.

Phase 3

1 4

REGN5713

Regeneron

Phase 3

1 5

REGN5715

Regeneron

Phase 3

1 6

Bilaxten

MMenarini International Operations Luxembourg SA

Phase 3

—7

Bepreve

BBausch Health Americas, Inc.

Phase 2

3 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 2

—9

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

—10

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Conjunctivitis1 trial

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Completed·XXencor, Inc.·Phase 1·NCT02148744·72 enrolled

Unspecified1 trial

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

Completed·XXencor, Inc.·Phase 1·NCT02881853·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for XmAb7195. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XmAb7195 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XmAb7195. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xencor, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: XXencor, Inc.

XmAb7195

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Conjunctivitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News